Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | USP14 | P54578 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138982 | 0.88 | CYP1A2 (0.42) | — | |
| SCHEMBL3138665 | 0.86 | NOTUM (0.46) | SLC6A2SLC6A4SLC6A3CHRM1NOTUM | |
| SCHEMBL3143109 | 0.81 | MAPT (0.47) | PDE4BNOTUM | |
| SCHEMBL6620647 | 0.80 | NOTUM (0.48) | SLC6A2SLC6A4SLC6A3CHRM1NOTUM | |
| SCHEMBL5832346 | 0.78 | NOTUM (0.51) | SLC6A2SLC6A4SLC6A3CHRM1NOTUM | |
| SCHEMBL3135365 | 0.78 | KMT2A (0.42) | SLC6A2SLC6A4SLC6A3CHRM1NOTUM | |
| SCHEMBL3138469 | 0.78 | CHRNB2 (0.47) | PDE4BRAD51F10 | |
| SCHEMBL22209952 | 0.75 | TRPA1 (0.38) | PDE4BSLC6A2SLC6A4SLC6A3RAD51 | |
| SCHEMBL31319984 | 0.74 | RAD51 (0.40) | PDE4BUSP14RAD51CHRM2CHRM5 | |
| SCHEMBL31319985 | 0.74 | AR (0.43) | PDE4BUSP14SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071598-B2 | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2011-12-06 | — | — | US | claimed |
| US-20100160333-A1 | NOVEL 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2010-06-24 | — | — | US | claimed |
| US-20090036456-A1 | 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2009-02-05 | — | — | US | claimed |
| EP-1984365-A1 | 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-10-29 | — | — | EP | claimed |
| WO-2007090886-A1 | 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-08-16 | — | — | WO | claimed |
| US-8071598-B2 | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2011-12-06 | — | — | US | disclosed |
| US-20100160333-A1 | NOVEL 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2010-06-24 | — | — | US | disclosed |
| US-7700596-B2 | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-04-20 | — | — | US | disclosed |
| US-20090036456-A1 | 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2009-02-05 | — | — | US | disclosed |
| EP-1984365-A1 | 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090886-A1 | 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160333-A1 | NOVEL 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A3, SLC6A2 | PDE4B 454/4885USP14 3633/4885SLC6A2 3/4885 |
| US-20090036456-A1 | 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | PDE4B 334/4885USP14 3631/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.